Precigen (STU:I5X) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:I5X Precigen Inc STU:I5X
66 GF Score
Price €4.32
GF Value €5.32
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Precigen Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Precigen's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

STU:I5X vs KARD, SLBT, GENB: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Precigen's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Precigen Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Precigen's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Precigen's Margin of Safety % (DCF Dividends Based) falls into.


STU:I5X
66GF Score
Precigen Inc STU:I5X
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Precigen (STU:I5X) Overvalued in 2026?

Based on GuruFocus' analysis, Precigen stock appears to be undervalued. The current stock price of €4.32 is trading 18.8% below its estimated GF Value™ of €5.32. GuruFocus considers Precigen to be Modestly Undervalued.

Key valuation signals for STU:I5X:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: €5.32 vs. price of €4.32 (18.8% below fair value)
  • GF Score™: 66/100 with 8 warning signs

No single metric tells the full story. See the STU:I5X stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Precigen Business Description

Other Exchanges PGEN:USA
Address 20374 Seneca Meadows Parkway, Germantown, MD, USA, 20876
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
66GF Score

Get the complete analysis for STU:I5X

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.32
Price
€5.32
GF Value